News February 14, 2024 Funding Announcement: Drs. D. Lansing Taylor, Mark Miedel, Alejandro Soto-Gutierrez, Mark Schurdak, and Lawrence Vernetti have received funding from NCATS for a five year grant establishing one of four Translational Centers for MPS (TraCe). This award is a collaborative effort with both NCATS and the FDA focused on qualifying our patient-derived biomimetic liver MPS as drug discovery tools in multiple Contexts of Use including drug metabolism, toxicity, drug efficacy testing and clinical trial cohort selection. February 14, 2024 Funding Announcement: Drs. Mark Miedel and Alejandro Soto-Gutierrez have received an RO1 from the NIDDK to implement a QSP platform to predict and test drugs for metabolic-associated steatotic liver disease genetic variants in an iPSC-cell based human biomimetic liver microphysiology system. December 14, 2023 Drs. Andreas Vogt and Mark Schurdak have received NIH funding in collaboration with Haitao Guo in the Department of Microbiology & Molecular Genetics for the project: High throughput screening and preclinical development of HBV cccDNA inhibitors. September 21, 2023 Dr. Mark Schurdak will be participating in the National Institute on Aging (NIA) Division of Geriatrics and Clinical Gerontology (DGCG) workshop on “Computational and Human In Vitro Approaches to Accelerate Translational Aging Research” on October 23 – 24, 2023 in Bethesda, MD. September 21, 2023 Funding Announcement: Drs. Andreas Vogt and Mark Schurdak have received SBIR funding in collaboration with Qrono, Inc., a Pittsburgh-based immunotherapy company, for the project: Screening for Tolerogenic Adjuvants to Enhance Antigen Specific Immunotherapy for Celiac Disease. September 21, 2023 Funding Announcement: Drs. Mark Miedel and Alejandro Soto-Gutierrez have received a contract from NCATS PaVe GT to produce an Acidemia liver MPS using iPSCs for gene therapy testing. August 1, 2023 Dr. D. Lansing Taylor will be the keynote speaker at the Society of Biomolecular Imaging and Informatics meeting in Boston, MA on October 31, 2023. The title of his lecture will be: “My Perspective on the Evolution of High Content Screening/Imaging and Phenotypic Drug Discovery”. August 1, 2023 Funding announcement: Dr. Lawrence Vernetti has received an SBIR grant in collaboration with Numa Biosciences (formerly Nortis, Inc.) beginning August 1, 2023 for “A liver-on-chip platform to evaluate panels of clinically relevant gene variants for screening of xenobiotic compounds”. August 1, 2023 Dr. Lawrence Vernetti will present a webinar to AnaBios entitled: “ Use of Human Liver Cells in Microphysiology Systems” to take place August 31, 2023 at 11 am EDT. June 28, 2023 BioSystics, Inc., a database and analytics company, announced that it has merged with Nortis, a microphysiology systems platform company, to form Numa Biosciences, Inc., a precision medicine platform company. 1 2 3 … 9 Next »